A Phase 1 Open-Label Study of PF-07985045 as a Single-Agent and in Combination with Other Anti-Cancer Agents in Participants with Advanced Solid Tumors

The purposes of this research study are (1) to learn about the safety and the effects of study drug, PF-07985045 on your specific cancer and on your body, with or without combination drugs and (2) to find the best dose for treating your specific type of cancer, as well as treating other types of cancers. This study is divided in two parts: Part 1 and Part 2. Part 1 testing and results applies to the study drug alone, called monotherapy. The goal of Part 1 is to determine the maximum tolerated dose (highest dose that is safe and tolerable in study participants, called MTDM and the recommended dose for expansion (the dose to give to many other participants, called the RDEM,). Part 2 testing and results involve a combination of PF-07985045 along with other anti-cancer drugs. The goal of Part 2 is to determine safety, tolerability, and whether PF- 07985045 in combination with other cancer treatments such as pembrolizumab, FOLFOX, cetuximab, gemcitabine, or nab-paclitaxel, effectively stabilize or improve your cancer. PF- 07985045 has not been approved by the Food and Drug Administration (FDA). This is the first studying PF-07985045 in humans.

Are you Eligible? (Inclusion Criteria)

• Must be 18 years old or older - Must be negative for COVID-19 - Must not have active bleeding disorder